Method of treating urethral syndrome in females
SUBSTANCE: invention refers to medicine, namely medicine, and may be used for treating urethral syndrome in females with using the antibacterial preparation gentamycin. Gentamycin is introduced into a urethral wall in the amount of 80 mg dissolved in anaesthetic solution 2 ml. The above preparation is introduced in parallel with the urethral wall. The anaesthetic is presented by 0.25% Novocaine. That is followed by a vulvar exposure to an infrared laser light at wave length 0.82 mcm, frequency 3000 Hz, and power 10 mWt. A procedure length makes 5-6 minutes; the therapeutic course is 8-10 procedures.
EFFECT: method is well tolerated, accessible and high effective by providing the high gentamycin concentration in the area of inflammation and stimulating repair processes.
1 ex, 2 tbl, 1 dwg
The invention relates to medicine, namely to urology.
The urination is common in women often: up to 90% at least once in their lifetime experienced dysuria. Infectious-inflammatory diseases of the lower genital tract in women are widely distributed throughout; this problem is discussed in many research studies [1, 2].
Along with the classic acute or recurrent cystitis, when the clinical picture is clear and is fast painful urination in the presence in the urine of bacteria, high levels of leukocytes and erythrocytes, often formed the urethral syndrome. The urethral syndrome in women due to chronic inflammation paraurethral glands of the Skin (skinit)that are inaccessible to antibiotics in the standard of their appointment (per os, intramuscularly, intravenously). Patients with urethral syndrome is often mistakenly treated as patients with cystitis, and the correct diagnosis is established only in the case of suppuration skanevik glands that requires surgical benefits.
Conventional antibiotic therapy appointment urotropin drugs (furamag, monural, ceforal) is the closest analogue, but these drugs are intended only for receiving per os, the local introduction impossible.
Gentamicin is a drug for parenteral therapy inside the muscle injection of gentamicin was adopted us for prototypal injected in the gluteal muscle gentamicin is distributed evenly through the body, not creating the maximum concentration in the lesion.
With the aim of increasing concentrations of drugs in inflammation and stimulation reparatory processes, a Method for treatment of urethral syndrome in women with antibacterial agents, characterized in that the wall of the urethra injected with 80 mg of gentamicin, dissolved in 2 ml of 0.25% novocaine with subsequent exposure of the vulva by the radiation of the infrared laser wavelength of 0.82 μm, a frequency of 3000 Hz, 10 mW, the duration of the procedure 5-6 minutes over a course of 8-10 treatments.
The method is as follows. The patient is placed in a gynecological chair with diluted legs, exposing the outer opening of the urethra by introducing transparent disposable vaginal mirrors Cuzco. The outer opening of the urethra and the anterior wall of the vagina treated with 1% aqueous solution of chlorhexidine, and then parallel to the wall of the urethra injected with 80 mg of gentamicin in 2 ml of 0.25% solution of novocaine. After that, the area of the urethra is irradiated with an infrared laser parameters: wavelength of 0.82 μm, the radiation frequency is 3000 Hz, the power is 10 MW. Duration of exposure for 5-6 minutes, in the course of 8-10 treatments.
After treatment in patients with firmness were relieved pain and restored the settings urination, stopped dyspareunia.
Example. Patient E., Hada. History - defloration cystitis, chronic cystitis with frequent exacerbations. Non-specific antibiotic therapy was rendered incomplete and short-lived effect. When viewed on the seat detected: the walls of the urethra thickened, painful on palpation; the external opening of the urethra swollen. The treatment by the proposed method for the treatment of urethral syndrome in women. 80 mg of gentamicin in 2 ml of 0.25% solution of novocaine injected into the wall of the urethra with the subsequent exposure of the vulva by the radiation of the infrared laser wavelength of 0.82 μm, a frequency of 3000 Hz, 10 mW, duration of treatment 6 minutes, for a course of 10 treatments (given the duration of the disease and the severity of clinical changes, the selected maximum duration of therapy and the maximum number of procedures). After 10 days fully cropped pain, urination free, painless, uroflowmetric counts are within the norm.
The method of treatment of urethral syndrome in women tested in the fgbi NIIT six patients; the results are presented in tables 1 and 2 and the chart.
|Dynamics data uroflowmetry on the treatment|
|Index||Ref the bottom||After the treatment|
|T voiding (C)||16,5||18,7|
|Q max (ml/s)||19,7||27,1|
|Q ave (ml/s)||5,0||12,8|
As follows from table 1, the initial volume of the bladder were patients in an average of just 165,2 ml after treatment has increased to over 253.7 ml Significantly increased after treatment average (Q ave)and maximum (Q max) urine flow rate.
|The severity of clinical manifestations of the source (abs./%), n=6|
there is no sign
|Pain during filling of the bladder||0||0||0||27,8%||22,2%||50,0%|
|Burning at the end of urination||0||0||0||47,2%||33,3%||19,4%|
|Discomfort after urination||0||0||5,5%||13,9%||38,9%||31,7%|
From table 2 it follows that at inclusion in the study all patients had serious violation of urination, with pronounced complaints; their change in the course of treatment reflects chart (see Fig.). Starting from the first day, all patients noted a decrease in urethral pain syndrome, 7-th day - improving the analysis of urine to normalize the majority of them, to the 10th - recovery. The proposed method is highly effective, well tolerated, available for use at hospitals and ambulatory is.
1. Pushkar DU, Zaitsev AV, BORIS Godunov., Davidians A.A. Diagnosis and treatment of various forms of cystitis in women. - M., 2002 - 39 C.
2. Rafalski CENTURIES, Stratchounski L. C., Kogan M.I. and other Antibacterial therapy of complicated urinary tract infections in outpatients. // Urology. - 2004. No. 5. - S-31.
The method of treatment of urethral syndrome in women antibiotic drug gentamicin, which is injected into the wall of the urethra in the amount of 80 mg dissolved in 2 ml of anesthetic solution, characterized in that the introduction is carried out parallel to the wall of the urethra, and as an anesthetic injected with 0.25%solution of novocaine with subsequent exposure of the vulva by the radiation of the infrared laser wavelength of 0.82 μm, a frequency of 3000 Hz, 10 mW, the duration of the procedure 5-6 min on a course of 8-10 treatments.
SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.
EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.
28 cl, 233 ex, 29 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is peroral pharmaceutical composition for treatment of urinary retention, caused by opioids, which includes, at least, one opioid antagonist naloxone or its pharmaceutically acceptable salt (versions).
EFFECT: disclosed is achievement of claimed intention, with naloxone possessing very low peroral bioavailability, and does not prevent (does not reverse) pain-killing action of opioid agonist.
17 cl, 19 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: it has been confirmed that the new azolcarboxamide compound or its pharmaceutically acceptable salt wherein a thiazole ring or an oxazole ring is bound to a benzene ring, a pyridine ring, a pyridazine ring, a thiophen ring, a pyrazole ring or a pyrrol ring through carboxamide or its ring possess high activity of receptor trkA inhibition; it has been found that they may be used as a therapeutic and/or preventive agent which is different in the fact concerning the effectiveness and safety for repeated urination, frequent micturate urge and urine incontinence associated with various urogenital diseases, including higher bladder activity, various lower bladder diseases accompanied with urogenital pain, such as interstitial cystitis, chronic prostatitis and others, and various diseases accompanied by pain; thereby the present invention has been created.
EFFECT: provided therapeutic and/or preventive agent for repeated urination, frequent micturate urge and urine incontinence associated with various urogenital diseases, including higher bladder activity, various lower bladder diseases accompanied with urogenital pain, such as interstitial cystitis, chronic prostatitis and others, and various diseases accompanied by pain on the basis of excellent inhibitory action on the receptor trkA.
24 cl, 1195 ex, 215 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention is related to pharmaceutics and medicine. The composition for urine incontinence contains fragments of viable muscular tissue and a carrier with the fragments of muscular tissue having a particle size from approximately 0.1 to approximately 3 mm3. The method of treating urine incontinence involves injections of the composition into urogenital tissue and into colorectal tissue. The method of preparing the composition involves the stages of producing at least one fragment of viable muscular tissue and combining said fragment with a carrier to be injected into urogenital tissue.
EFFECT: use of the declared invention enables higher clinical effectiveness in urine incontinence, particularly stress-induced urine incontinence ensured by the use of the composition.
12 ex, 7 tbl
SUBSTANCE: invention relates to a compound of formula (II-A) or pharmaceutically acceptable salt thereof: [in which symbols denote the following: R10-R12: are identical or different and each denotes halogen, lower alkyl, halogen-lower alkyl, -OR0, -O-halogen-lower alkyl or -CN, R13: R0, halogen, halogen-lower alkyl, -OR0, -O-halogen-lower alkyl or -CN, ring B: benzene ring or a 5-6-member heteroaromatic ring containing 1-2 heteroatoms selected from O, S and N, R14: R0, halogen or -OR0, R0: are identical or different and each denotes H or lower alkyl, Y1: a single bond, lower alkylene, lower alkenylene or O-lower alkylene-, and Z1: -CO2R0 or -C0-NH-SO2-lower alkyl]. The invention also relates to a pharmaceutical composition based on the said compound, having antagonistic effect on the EP1 receptor.
EFFECT: obtaining novel compounds and a pharmaceutical composition based on said compounds, which can be used in a medicinal agent for treating lower urinary tract symptoms.
6 cl, 56 tbl, 231 ex
SUBSTANCE: invention relates to use of a therapeutic agent which is an α-amino-amide compound of formula (I):
, in which R is a phenyl ring which is optionally substituted with one or two substitutes independently selected from halogen, hydroxy, cyano, C1-C6-alkyl, C1-C6-alkoxy or trifluoromethyl; R1 is hydrogen or C1-C6-alkyl; R2 and R3 are independently selected from hydrogen, C1-C4-alkyl; R4 and R5 independently denote hydrogen, C1-C6-alkyl; X is O or S; Y and Z, taken together with X and a phenyl ring bonded to Y and X, form a 5-7-member saturated heterocycle containing O or S atoms, or Y and Z denote hydrogen; or its isomers, mixtures and pharmaceutically acceptable salts for preparing a medicinal agent for treating lower urinary tract disorders.
EFFECT: obtaining a pharmaceutical composition based on the said compounds.
8 cl, 6 ex
SUBSTANCE: invention relates to medicine, namely to inflectional diseases, and can be applied for treatment of patients with haemorrhagic fever with renal syndrome of medium- severe forms. For this purpose traditional basic therapy is carried out and since first day of disease additionally by intravenously drip introduced is medication emoxypin. Since 6-th day of therapy 1% emoxypin is introduced intramuscularly in amount 0.5 ml 2 times per day during 10 days.
EFFECT: method insures reduction of treatment terms, also due to improvement of nitrogen-excretion renal function, reduction of endotoxicosis, improvement of oxidative reactions and immunomodulaton.
7 tbl, 2 ex
SUBSTANCE: invention concerns N-phenylphosphoric acid triamides of general formula (I), method of their obtainment and application as inhibition agents in enzymic hydrolysis of carbamide , where X is oxygen or sulphur; R1, R2, R3, R4 are selected out of hydrogen, C1-C8 alkyl, alcoxy, fluorine, chlorine, bromine, iodine, trifluoromethyl.
EFFECT: obtaining novel efficient urease inhibitors.
12 cl, 4 ex, 1 tbl
SUBSTANCE: invention refers to medicine, urology, physiotherapy and to be used in the patients suffering from chronic pyelonephritis accompanied with chronic prostatitis and chronic cystitis. The method involves taking the mineral water of the Slavjanovsky source dosed 3 - 5 ml per kg of body weight, combined with carbonic mineral baths 35-37°C for 15 minutes 3 times a day, № 8-10, mud "panties" at 40-42°C within 30 minutes to 1.5 hours, prostate massage № 8-10, additionally 50-60 minutes later followed with electropulse therapy combined with exposure to laser magnetic rays. Electropulse therapy involves low-frequency, low-voltage pulse current with a spherical unipolar electrode. Exposure is contact, labile, clockwise and located at skin projection of ascending, transverse and descending large intestine at frequency 30.2 Hz within 8-10 minutes. The course of treatment is 10-12 procedures.
EFFECT: method improves life quality of the patients both in latent phase of inflammatory process, and in mild and moderate active chronic process.
2 ex, 2 tbl
SUBSTANCE: present invention pertains to crystalline substance for peroral solid medicinal preparation, which is an indoline compound (KMD-3213), which exhibits blocking action to α1-adrinaline receptors, is suitable for use as a therapeutic medium in case of dysuria and is represented by formula (I) . The x-ray diffraction picture of the powder of this compound is characterised by main peaks 5.5°±0.2°, 6.1°±0.2°, 9.8°±0.2°, 11.1°±0.2°, 12.2°±0.2°, 16.4°±0.2°, 19.7°±0.2° and 20.0°±0.2°, as 2θ.
EFFECT: obtaining solid medicinal preparations for treating dysuria, containing this crystalline substance as an active ingredient.
14 cl, 3 dwg, 2 tbl, 9 ex
SUBSTANCE: group of inventions refers to medicine, treating a cervical pathology associated with a high-oncogenicity human papilloma virus (HPV) infection. To eliminate the HPV for the purpose of the prevention of cervical cancer, a cervical mucosa is coated with a layer of a carbon dye and exposed to a laser light. What is used is a pulse-periodic generation mode having the following parameters: power flow density 2-10 J/cm2, radiation pulse duration 10-4 -10-2 sec, pulse repetition rate 1-5 Hz, wave length 0.8-1.1 mcm. A device for implementing the method comprises a laser working in the above mode with the above parameters, a modulator, a control and indication unit for laser parameter setting by the modulator, a parameter measurement unit for laser control, a controlled microinjector, a carbon dye delivery and radiation system actuated by the controlled microinjector, a probing laser for controlling the carbon dye layer thickness.
EFFECT: group of inventions provides eliminating the HPV from the cervical surface, controlling the thermal exposure area, its safety with avoiding an uncontrolled, irreversible injury of the cervical surface and the uterine itself.
8 cl, 1 dwg, 5 ex
SUBSTANCE: invention relates to medicine, particularly to ophthalmology. What is involved is a brachytherapy of an intraocular melanoma with a size of more than 6.5 mm by anchoring a beta-applicator with ruthenium-106 +rhodium-106 to an episclera for 7-14 days on a projection of the melanoma at total radiation dosage 3000 Gy. The brachytherapy is combined with a diode-laser transpupillar therapy of the melanoma at radiation power 800 mWt. Then, 6-12 months after the beta-applicator has been removed, a restrictive retinal coagulation at power 500 mWt and an endoresection of the residual melanoma follow. The method enables avoiding such complications, as vitreous body and retina haemorrhage, retinal detachment, complete loss of vision, as well as reducing a probability of metastases due to the preliminary brachytherapy and the following restrictive retinal laser coagulation.
EFFECT: combined application of the thermal therapy and brachytherapy enables affecting the melanoma from both sides for more complete destruction of its structure.
SUBSTANCE: invention refers to medicine, namely gynaecology, physiotherapy. A method involves the integrated treatment of the patients with genital endometriosis and hysteromyoma. The treatment involves taking mineral water, observing a biologically programmed light pattern, taking radon baths and radon gynaecological irrigations and small enemas, as well as conducting a laser therapy of biologically active points (BAPs). The patients take carbonated chloride-hydrocarbonate-sulphate sodium-calcium warm Narzan water taken from sources No. 4, No. 7 and No. 24, 3.4 mg per kg 3 times ad day, 40 minutes before meals. The radon baths are taken with the radon concentration of 1.5 kBq/l. The radon gynaecological irrigations and microenemas are performed with the radon concentration of 6.5 kBq/l, temperature 36°C, for 15 minutes within the course of 10-12 procedures. The BAP laser therapy is conducted in an autoresonant mode. The BAPs of anterior median meridian are covered, including: 1-2 (qu-gu), 1-3 (zhong-ji), 1-4 (guan-yuan), 1-5 (shi-men), 1-7 (yin-jiao); renal meridian: R-12 (da-ho), R-13 (qi-xu), R-14 (si-man), R-15 (zhong-zhu), R-16 (huang-shu); bladder meridian: V-31 (shang-liao), V-32 (ci-liao), V-33 (zhong-liao), V-34 (xia-liao); posterior median meridian: T-2 (yao-shu), T-3 (yao-yang-guan), T-4 (min-man), T-5 (xuan-shu). Using the radon baths of the different radon concentrations 'softens' an effect of the absorbed radiation dose on the homeostasis systems and preserves an effect of a high absorbed dose on the genital system. The laser therapy in the autoresonant mode within pathological BAPs improves the accuracy of the exposure on the pathological processes within a target organs.
EFFECT: method prolongs the remission, normalises the hormonal ratios in the remote period.
2 dwg, 4 ex
SUBSTANCE: invention relates to medicine, particularly to ophthalmology. That is ensured by the integrated treatment involving the single macular exposure to a sublimit micro-pulse infrared laser light. That is combined with the ozone therapy using drug preparations with underlying mixed gas agitation. That is followed by an antioxidant therapy consisting of local instillations of emixipin and oral administration of complivit oftalmo.
EFFECT: method enables the therapy of predisciform age-related macular degeneration at the stage of confluent drusens, preventing the development of the disease and improving the visual acuity.
SUBSTANCE: invention refers to medicine, namely to surgery, and may be used in treating trophic ulcers and infected persistent wounds. That is ensured by the exposure to an argon plasma flow in a dose of 100-250 J/cm2 at 10-25 cm from the treated surface. The exposure length on one field makes 10-25 seconds. The sound surface treatment is followed by the dynamic exposure to a running argon plasma flow at 10-20 cm in a dose of 80-150 J/cm2 over the whole wound surface to form a gloss on the wound surface.
EFFECT: method provides the effective treatment of the given pathology ensured by specifying a mode of the exposure causing the microorganism elimination, wound surface drying, sudden perifocal oedema reduction, as well as epithelial cell growth stimulation on the periphery of the wound, as well as on its free surface.
SUBSTANCE: invention refers to medicine. A method of treating the patients with the complicated forms of diabetic foot by blood sampling, centrifugation, plasma removal, erythrocyte fraction recovery, introduction of the angiotropic drug alprostadil, exposure to laser light at power 12 mWt for 20 minutes, addition of normal saline 100 ml in erythrocyte fraction 200 ml and reinfusion for 1.5-2 hours; ATP 2 ml is combined with the angiotropic drug alprostadil and introduced into the erythrocyte fraction; the erythrocyte fraction is reinfused every second day, alternated with intravenous drop-by-drop introduction of Vessel-DUE-F 600 LSU and actovegin 5 ml per normal saline 100 ml; the therapeutic course is 10 days.
EFFECT: using the method provides higher effectiveness and reduces the length of treatment of the patients with the complicated forms of diabetic foot syndrome, promotes the longer preservation of the achieved therapeutic effect.
SUBSTANCE: invention refers to medicine. Treating nosocomial sinusitis in resuscitation and intensive care units is ensured by nasal cavity clearance and sinus irrigation according to the common technique using a Kulikovsky's needle. The solution of polymyxin E in the concentration of 133 mcg/ml is introduced for 10 minutes before sinus administration of a photosensitiser that is methylene blue 20 ml in the concentration of 15 mcg/ml. The contents are aspirated with a syringe. The sinus mucosa is exposed to laser light through a dissipative light guide introduced through the Kulikovsky's needle at wave legnth 660 nm, power 500 mWt, emission length 23.5 minutes.
EFFECT: method enables enhancing the photodynamic effect on the gram-negative microorganisms ensured by including polymyxin E relieving the photosensitiser adhesion on the surface of a gram-negative bacterial cell into the method of the photodynamic therapy.
2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, namely - to physiotherapy, urology. A method involves the integrated physiotherapeutic effect of three physical factors. The ultrasonic exposure is characterised by frequency 2.7 kHz + 0.2 kHz, length 9 ms, pulse period 200 ms. The exposure to magnetic field is characterised by magnetic induction amplitude 1300 mT, pulse period 80 ms. The laser exposure is characterised by power 5.0 Wt, frequency 80 Hz. Total duration of a procedure is 30 minutes.
EFFECT: due to using the sequential effect of three physical factors, the method reduces the period of small urolith evacuation, the intensity of pain syndrome, requirement in analgesic and anti-spasmodic drugs, minimises the development of sclerotic changes in the ureter wall that improves urinary outflow and reduces a risk of recurrent urolith formation.
SUBSTANCE: invention refers to medicine, namely - to neurology. The method involves the integrated treatment. Azathioprine, dexamethasone and analgin are administered into the patient. Azathioprine 50 mg is administered three times a day, after meals for 21 days. Dexamethasone 4 mg is administered intramuscularly three times a day for 15 days. From the 16th to 18th day of treatment, dexamethasone 4 mg is administered 2 times a day - in the morning and afternoon. From the 19th to 20th day, the same is administered in a dose of 4 mg in the afternoon. Before bedtime, 50% analgin 2.0 ml is administered parenterally for 10 days. At 9 o'clock in the morning, patient's lumbar pain area is exposed to the magnetic laser treatment. The patient is exposed to infrared light of wave length 0.8-0.9 mcm, pulse power 5-8 Wt, pulse frequency 1000 Hz and magnetic strength 35 mT. The exposure is contact and stable, and covers the fields paravertebrally. The length of the one-field exposure is 2 minutes. The therapeutic course is 15 procedures. Trives spinal assistant is put on in the horizontal position of lying on back. The spinal assistant is taken off in the horizontal position before bedtime.
EFFECT: method reduces the length of treatment, prolongs a remission, including due to the developed modes and combinations of the various components of the exposure.
1 ex, 1 tbl
SUBSTANCE: invention refers to medicine, namely to - physiotherapy, to infectious diseases. The method involves the integrated use of drug preparations, magnetic and laser therapy. The laser therapy is differentiated depending on the severity, modified leukocytal intoxication index (mLII), malondialdehyde (MDA), lipid hydroperoxide (LHP), antioxidant activity (AOA), interleukin-1β (IL-1β), tumour necrosis factor (TNF-α). The mild severity, mLII within the range of 2.8±0.09-3.44±0.07, MDA 3.7±0.08-4.2±0.07mcm/ml, LHP 10.1±0.1-11.3±0.09 mcm/ml, AOA 0.489±0.005-0.390±0.007, IL-1β 25.3±0.5-26.71±0.3 pg/ml; TNF-α 37.1±0.5-45.7±0.8 pg/ml require the daily percutaneous exposure to a constant magnetic field and low-intensity laser light of power 55 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours. The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 60 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power min. 5 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by a light guide tip. The length of the exposure is 120 minutes. The therapeutic course consists of 5 procedures. The moderate severity, mLII 4.18±0.08-6.06±0.07, MDA 4.9±0.03-5.6±0.02 mcm/ml, LHP 12.3±0.08-14.7±0.07 mcm/ml; AOA 0.345±0.007-0.315±0.006, IL-1β 27.1±0.2-28.1±0.1 pg/ml, TNF-α 57.7±0.9-72.1±0.5 pg/ml requires the daily percutaneous exposure to the constant magnetic field and low-intensity laser light of power 60 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours. The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 90 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power 7 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by the light guide tip. The length of the exposure is 150 minutes. The therapeutic course is 7 procedures. The severe condition, mLII 7.76±0.08-8.06±0.07, MDA 7.1±0.03-11.6±0.02 mcm/ml, LHP 16.3±0.08-19.7±0.07 mcm/ml; AOA 0.310±0.007-0.294±0.006, IL-1β 30.1±0.2-31.1±0.1 pg/ml, TNF-α 76.7±0.9-85.1±0.5 pg/ml requires the daily percutaneous exposure to the constant magnetic field and low-intensity laser light of power 60 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 120 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power 9 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by the light guide tip. The length of the exposure makes 180 seconds. The therapeutic course consists of 9 procedures. For the first five days, all the patients are prescribed with heparin electrophoresis by common technique during afternoon.
EFFECT: method reduces a rate of recurrence.
3 tbl, 3 ex
SUBSTANCE: invention refers to medicine, namely to neurosurgery, resuscitation and neurology, and may be used for treating the permanent unconscious vegetative state. That is ensured by intratympanic streptomycin treatment with underlying common drug therapy of the state. The completion of the above is followed by the electric transcranial exposure on the brain. For the intratympanic treatment, streptomycin 1 g is dissolved in physiologic saline 1 ml. The preparation is introduced once a day from one side, and on the other day from the opposite side. The therapeutic course is 5-10 days. The electric transcranial exposure is presented by transcranial DC micropolarisation of intensity 200-400 mcA for 30-40 minutes daily for 16-24 days. The exposure is performed through 3-4 electrodes places on the areas of temporo-caudal projections and posterior associated cortical areas from both sides. For the first 6 days, such exposure covers the temporo-caudal projections, while on the other days the posterior associated cortical area projections are exposed. If required, the above therapeutic courses are repeated not earlier than in 3 months until the clear consciousness is reached.
EFFECT: method provides an immediate and convincing clinical effect without brain invasiveness, an ability to recover the clear consciousness in these patients, as well as a significant reduction of the pathologically increased muscle tone and as a result, achieved satisfactory level of the patient's self-service.